Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Herpes zoster vaccine may be used in RA patients receiving cDMARD, low-dose GC

13 Apr 2018
A need for greater awareness: Vaccination may be common among children, but Singaporean adults fail to see the need for it.

A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).

Additionally, the vaccine-induced VZV-specific cellular immune response is weaker in patients with RA than in those with osteoarthritis (OA), but the vaccine may still be considered in RA patients receiving conventional disease-modifying antirheumatic drugs (cDMARD) and/or low-dose glucocorticoids (GC).

None of the patients developed vaccination-induced HZ during follow-up (median, 1.6 years). The VZV-specific enzyme-linked immunospot spot-forming units and anti-VZV immunoglobulin G antibodies significantly increased in patients with RA and OA who received the HZ vaccine. Patients with RA had lower spot-forming units than those with OA both at baseline and at 12 weeks after vaccination.

The disease activity index for patients with RA was similar at baseline and at 12 weeks post-HZ vaccination. However, flare developed in six patients with RA during the 12 weeks. A total of 17 (24.6 percent) participants reported a mild adverse event, such as an injection site reaction (11.6 percent).

This observational study of a live attenuated HZ vaccine included 41 patients with RA receiving cDMARD and/or low-dose GC and 28 patients with OA. Blood samples were taken before and at 12 weeks post-HZ vaccination.

The authors assessed immunogenicity using VZV-specific interferon gamma ELISA and an in-house ELISA. They analysed clinical outcomes, including adverse events, HZ occurrence and RA flares.

A recent study by Gagliardi ang colleagues showed that HZ vaccine was well-tolerated and effective in preventing HZ disease, with protection lasting for 3 years. [Cochrane Database Syst Rev 2016;3;3:CD008858]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.